| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Antibody–Drug Conjugates in Uro-Oncology
|
Sigorski, Dawid
|
|
|
17 |
3 |
p. 203-221
|
artikel
|
| 2 |
A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study
|
Salawu, Abdulazeez
|
|
|
17 |
3 |
p. 271-281
|
artikel
|
| 3 |
Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era
|
Ishihara, Hiroki
|
|
|
17 |
3 |
p. 307-319
|
artikel
|
| 4 |
Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study
|
Trippett, Tanya
|
|
|
17 |
3 |
p. 283-293
|
artikel
|
| 5 |
Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies
|
Shimizu, Toshio
|
|
|
17 |
3 |
p. 377
|
artikel
|
| 6 |
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
|
Scott, Lesley J.
|
|
|
17 |
3 |
p. 381
|
artikel
|
| 7 |
Correction to: MYL-1402O: A Bevacizumab Biosimilar
|
Lee, Arnold
|
|
|
17 |
3 |
p. 379
|
artikel
|
| 8 |
Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy
|
Mizukami, Takuro
|
|
|
17 |
3 |
p. 343-353
|
artikel
|
| 9 |
Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor
|
Kennedy, Laura C.
|
|
|
17 |
3 |
p. 329-341
|
artikel
|
| 10 |
Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review
|
McLean, Thomas D.
|
|
|
17 |
3 |
p. 223-252
|
artikel
|
| 11 |
Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC
|
Frampton, James E.
|
|
|
17 |
3 |
p. 369-376
|
artikel
|
| 12 |
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors
|
Choo, Joan R. E.
|
|
|
17 |
3 |
p. 355-368
|
artikel
|
| 13 |
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
|
Huang, Yen-Hsiang
|
|
|
17 |
3 |
p. 295-306
|
artikel
|
| 14 |
Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer
|
Klink, Andrew J.
|
|
|
17 |
3 |
p. 321-328
|
artikel
|
| 15 |
When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents
|
Araujo, Daniel V.
|
|
|
17 |
3 |
p. 253-270
|
artikel
|
Tijdschrift beschrijving